OLMA Stock Price, Olema Pharmaceuticals Quote, Chart

Market Summary

USD9.22-0.10

Market Closed

-1.07%

OLMA Alerts

1 major insider sales recently.

OLMA Stock Price

View Fullscreen

OLMA RSI Chart

OLMA Valuation

Market Cap

515.7M

Price/Earnings (Trailing)

-5.19

Price/Free Cashflow

-5.91

OLMA Price/Earnings (Trailing)

OLMA Profitability

Return on Equity

-42.04%

Return on Assets

-37.67%

Free Cashflow Yield

-16.93%

OLMA Fundamentals

OLMA Earnings

Earnings (TTM)

-99.3M

Earnings Growth (Yr)

-9.49%

Earnings Growth (Qtr)

-15.68%

Breaking Down OLMA Revenue

Last 7 days

-15.4%

Last 30 days

-15.1%

Last 90 days

-40.4%

Trailing 12 Months

32.3%

How does OLMA drawdown profile look like?

OLMA Financial Health

Current Ratio

9.61

OLMA Investor Care

Shares Dilution (1Y)

37.22%

Diluted EPS (TTM)

-2.01

Tracking the Latest Insider Buys and Sells of Olema Pharmaceuticals Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
May 06, 2024	harmon cyrus	sold	-54,600	10.92	-5,000	-
Apr 30, 2024	harmon cyrus	sold	-142,650	9.51	-15,000	-
Mar 28, 2024	harmon cyrus	sold	-219,400	10.97	-20,000	-
Mar 18, 2024	zojwalla naseem	acquired	66,719	4.87	13,700	chief medical officer
Mar 05, 2024	rappaport andrew	sold	-	-	-481,014	-
Mar 05, 2024	rappaport andrew	acquired	-	-	385,965	-
Feb 29, 2024	harmon cyrus	sold	-310,309	12.4124	-25,000	-
Feb 01, 2024	harmon cyrus	sold	-77,800	15.56	-5,000	-
Jan 31, 2024	harmon cyrus	sold	-305,750	12.23	-25,000	-
Jan 25, 2024	zojwalla naseem	acquired	140,400	7.02	20,000	chief medical officer

Which funds bought or sold OLMA recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 10, 2024	JPMORGAN CHASE & CO	reduced	-19.92	-141,864	259,058	-%
May 10, 2024	Pacer Advisors, Inc.	new	-	15,497	15,497	-%
May 10, 2024	Y-Intercept (Hong Kong) Ltd	sold off	-100	-158,806	-	-%
May 10, 2024	BlackRock Inc.	reduced	-1.45	-9,381,220	36,411,400	-%
May 10, 2024	Covestor Ltd	new	-	-	-	-%
May 10, 2024	DIMENSIONAL FUND ADVISORS LP	added	12.87	-2,151,520	21,917,300	0.01%
May 10, 2024	VANGUARD GROUP INC	reduced	-11.02	-10,708,700	27,255,000	-%
May 10, 2024	WELLS FARGO & COMPANY/MN	added	14.45	-9,088	109,578	-%
May 10, 2024	CITIGROUP INC	added	5,100	2,762,350	2,829,800	-%
May 10, 2024	ACADIAN ASSET MANAGEMENT LLC	reduced	-59.68	-2,422,000	1,167,000	-%

Are Funds Buying or Selling OLMA?

Are funds buying OLMA calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own OLMA

No. of Funds

OLMA Alerts

1 major insider sales recently.

Unveiling Olema Pharmaceuticals Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Mar 22, 2024	deep track capital, lp	5.44%	3,040,248	SC 13G
Feb 14, 2024	paradigm biocapital advisors lp	14.3%	7,903,600	SC 13G/A
Feb 14, 2024	kynam capital management, lp	-	0	SC 13G/A
Feb 14, 2024	cormorant asset management, lp	3.96%	2,181,800	SC 13G/A
Feb 12, 2024	janus henderson group plc	1.3%	700,100	SC 13G/A
Jan 29, 2024	blackrock inc.	6.0%	3,263,907	SC 13G
Nov 28, 2023	logos global management lp	7.8%	4,252,005	SC 13D/A
Sep 14, 2023	biotechnology value fund l p	8.6%	4,688,954	SC 13D/A
Sep 13, 2023	paradigm biocapital advisors lp	14.3%	7,803,600	SC 13G/A
Apr 10, 2023	paradigm biocapital advisors lp	6.2%	2,515,111	SC 13G

Recent SEC filings of Olema Pharmaceuticals Inc

View All Filings

Date Filed	Form Type	Document
May 08, 2024	10-Q	Quarterly Report
May 08, 2024	8-K	Current Report
May 07, 2024	4	Insider Trading
May 06, 2024	144	Notice of Insider Sale Intent
May 02, 2024	4	Insider Trading
Apr 30, 2024	144	Notice of Insider Sale Intent
Apr 26, 2024	ARS	ARS
Apr 26, 2024	DEF 14A	DEF 14A
Apr 26, 2024	DEFA14A	DEFA14A
Mar 29, 2024	4	Insider Trading

Peers (Alternatives to Olema Pharmaceuticals Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	48.2B	6.8B	19.54%	-2.80%	-8.07	7.03	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	19.0B	2.0B	0.98%	-26.98%	-57.12	9.47	75.20%	68.82%
BMRN	15.3B	2.5B	-12.72%	-14.31%	74.39	6.18	13.74%	186.89%
INCY	12.9B	3.8B	6.98%	-11.75%	17.35	3.43	8.58%	129.81%
MID-CAP
BBIO	5.3B	107.9M	6.22%	110.41%	-9.76	48.09	54.84%	-28.31%
APLS	5.2B	524.1M	-16.95%	-51.10%	-12.51	9.96	394.93%	39.61%
AXSM	3.6B	251.0M	9.36%	-4.29%	-12.12	14.31	73.58%	-86.73%
ARWR	2.7B	240.7M	-10.69%	-43.90%	-5.82	12.77	-1.03%	-213.43%
ACAD	2.5B	813.8M	-11.38%	-29.25%	-1.5K	3.08	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	6.64%	20.67%	29.44	4.66	60.38%	-34.49%
NVAX	1.8B	996.6M	206.31%	55.15%	-4.62	1.85	-26.66%	65.49%
CRBP	458.7M	881.7K	5.07%	336.18%	-13.59	481.06	-77.61%	33.36%
INO	294.6M	4.9M	3.08%	29.79%	-2.36	60.54	-54.97%	48.23%
IBIO	15.6M	2.1M	-10.40%	79.21%	-0.67	7.61	-13.45%	69.54%

Olema Pharmaceuticals Inc News

Latest updates

Olema Pharmaceuticals Inc Earnings Report: Key Takeaways & Analysis

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet														(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4
Assets	-4.8%	264	277	293	178	196	216	232	251	277	296	310	322	331	343
Current Assets	-5.4%	252	267	282	172	189	209	225	243	270	291	308	321	330	342
Cash Equivalents	-50.8%	34.00	69.00	117	35.00	41.00	24.00	27.00	25.00	22.00	14.00	26.00	50.00	48.00	339
Net PPE	6.7%	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	0.00
Liabilities	18.8%	27.00	23.00	18.00	16.00	21.00	18.00	14.00	14.00	12.00	11.00	9.00	8.00	5.00	5.00
Current Liabilities	21.3%	26.00	22.00	16.00	15.00	19.00	17.00	13.00	12.00	10.00	9.00	9.00	8.00	5.00	5.00
Shareholder's Equity	-6.9%	236	254	275	162	175	198	218	236	265	285	301	314	326	338
Retained Earnings	-10.1%	-336	-305	-278	-257	-237	-208	-182	-160	-127	-104	-82.55	-64.84	-48.43	-33.09
Additional Paid-In Capital	2.5%	573	559	554	419	413	408	403	399	394	389	383	379	374	371
Shares Outstanding	1.6%	56.00	55.00	55.00	41.00	40.00	40.00	40.00	40.00	40.00	40.00	40.00	39.00	-	-
Float	-	-	-	-	245	-	-	-	120	-	-	-	715	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																		(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4
Cashflow From Operations	-27.2%	-23,496	-18,476	-22,744	-22,116	-20,391	-19,711	-17,992	-26,459	-17,903	-18,603	-12,098	-8,905	-11,084	-9,013	-7,536	-1,181	-2,136	-
Share Based Compensation	12.8%	4,909	4,351	4,105	4,170	4,630	4,861	4,275	4,728	4,965	4,627	4,157	3,921	3,208	-	-	-	-	-
Cashflow From Investing	34.8%	-20,144	-30,915	-25,436	14,113	37,387	16,336	20,164	29,412	25,567	6,000	-12,784	10,930	-279,584	-51.00	10.00	-6.00	-9.00	-
Cashflow From Financing	1586.6%	8,821	523	130,629	2,043	220	273	106	64.00	33.00	818	57.00	-	-	219,789	84,874	23,754	29,986	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

OLMA Income Statement

2024-03-31

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Operating expenses:
Research and development	$ 29,883	$ 22,826
General and administrative	4,456	6,776
Total operating expenses	34,339	29,602
Loss from operations	(34,339)	(29,602)
Other income:
Interest income	3,352	1,305
Other income	17	11
Total other income	3,369	1,316
Net loss	$ (30,970)	$ (28,286)
Net loss per share, basic (in dollars per share)	$ (0.56)	$ (0.7)
Net loss per share, diluted (in dollars per share)	$ (0.56)	$ (0.7)
Weighted average shares used to compute net loss per share, basic (in shares)	55,574,324	40,354,493
Weighted average shares used to compute net loss per share, diluted (in shares)	55,574,324	40,354,493

OLMA Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 33,720	$ 68,539
Marketable securities	215,257	193,268
Prepaid expenses and other current assets	3,113	4,706
Total current assets	252,090	266,513
Operating lease right-of-use assets	2,055	2,291
Other assets and long-term deposits	9,549	8,141
Total assets	263,694	276,945
Current liabilities:
Accounts payable	7,656	2,698
Operating lease liabilities, current	1,057	988
Other current liabilities	17,511	17,935
Total current liabilities	26,224	21,621
Operating lease liabilities, net of current portion	1,152	1,429
Total liabilities	27,376	23,050
Commitments and contingencies (Note 10)
Stockholders' equity:
Preferred stock, $0.0001 par value; 10,000,000 shares authorized as of March 31, 2024 and December 31, 2023; no shares issued and outstanding as of March 31, 2024 and December 31, 2023.
Common stock, $0.0001 par value; 490,000,000 shares authorized as of March 31, 2024 and December 31, 2023; 55,932,127 and 55,097,118 shares issued as of March 31, 2024 and December 31, 2023, respectively; 55,867,863 and 54,992,784 shares outstanding as of March 31, 2024 and December 31, 2023, respectively.	4	4
Additional paid-in capital	572,926	559,176
Accumulated other comprehensive (loss) income	(10)	347
Accumulated deficit	(336,602)	(305,632)
Total stockholders' equity	236,318	253,895
Total liabilities and stockholders' equity	$ 263,694	$ 276,945

About Olema Pharmaceuticals Inc

Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1b/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.

CEO	Dr. Sean P. Bohen M.D., Ph.D.
WEBSITE	https://olema.com
INDUSTRY	Biotechnology
EMPLOYEES	67

Olema Pharmaceuticals Inc Frequently Asked Questions

What is the ticker symbol for Olema Pharmaceuticals Inc? What does OLMA stand for in stocks?

OLMA is the stock ticker symbol of Olema Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Olema Pharmaceuticals Inc (OLMA)?

As of Mon May 13 2024, market cap of Olema Pharmaceuticals Inc is 515.71 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of OLMA stock?

You can check OLMA's fair value in chart for subscribers.

What is the fair value of OLMA stock?

You can check OLMA's fair value in chart for subscribers. The fair value of Olema Pharmaceuticals Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Olema Pharmaceuticals Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for OLMA so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Olema Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether OLMA is over valued or under valued. Whether Olema Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Olema Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for OLMA.